Characterization of Epithelial IL-8 Response to Inflammatory Bowel Disease Mucosal E. coli and Its Inhibition by Mesalamine

Sreeedar Subramanian, MD,* Jonathan M. Rhodes, MD,* C. Anthony Hart, PhD,† Ben Tam, BSc,* Carol L. Roberts, MRes,* Shirley L. Smith, PhD,* John E. Corkill, MSc,‡ Craig Winstanley, PhD,† Mumtaz Virji, PhD,‡ and Barry J. Campbell, PhD*

---

Background: Mucosally adherent E. coli are found in inflammatory bowel disease (IBD) and colon cancer. They promote release of the proinflammatory cytokine interleukin-8 (IL-8). We explored mechanisms for this release and its inhibition by drugs.

Methods: IL-8 release from colon epithelial cells in response to mucosal E. coli isolates from IBD, colon cancer, and controls was characterized at the cellular and molecular level.

Results: IL-8 response of HT29 cells was greater with Crohn’s disease (689 ± 298 [mean ± SD] pg IL-8/mL at 4 hours, n = 7) and colon cancer isolates (532 ± 415 pg/mL, n = 14) than with ulcerative colitis (236 ± 58 pg/mL, n = 6) or control isolates (236 ± 100 pg/mL, n = 6, P < 0.0001). Bacterial supernatants contained shed flagellin that triggered IL-8 release. For whole bacteria the IL-8 response to E. coli that agglutinate red blood cells (548 ± 428 pg IL-8/mL, n = 16), a function that correlates with epithelial invasion, was greater than for nonhemagglutinators (281 ± 253 pg/mL, n = 17; P < 0.0001). This was particularly marked among E. coli that, although flagellate, could not release IL-8 from TLR5-transfected HEK293 cells. IL-8 release was mediated by extracellular-regulated kinase (ERK) and p38 mitogen-activated protein kinase (MAPK) and inhibited by mesalamine, but not hydrocortisone, at therapeutic concentrations.

Conclusions: Mucosa-associated E. coli shed flagellin that elicits epithelial IL-8 release but this may only become relevant when the mucosal barrier is weakened to expose basolateral TLR5. Adherent and invasive IBD and colon cancer E. coli isolates also elicit a flagellin-independent IL-8 response that may be relevant when the mucosal barrier is intact. The IL-8 release is MAPK-dependent and inhibited by mesalamine.

Key Words: Escherichia coli, inflammatory bowel disease, colon cancer, IL-8, flagellin, MAPK, mesalamine

---

Inflammatory bowel disease (IBD) is thought to result from an aberrant mucosal immune response to the gut microbiota. This is supported by evidence that various animal models of IBD all require the presence of commensal bacteria to develop inflammation. At least 7 independent studies have now reported an increased presence of adherent and invasive E. coli (AIEC) strains in Crohn’s disease (CD)2–8 and they have also been found in ulcerative colitis (UC)3,6,9 and colon cancer.4,6 Similar E. coli have recently been shown to be associated with granulomatous colitis in boxer dogs.10 They are present in both inflamed and uninfamed mucosa,4,6 suggesting that they are not just recruited as a consequence of inflammation and it is looking increasingly likely that they play an important role in IBD pathogenesis.

Although there is evidence of tissue invasion by E. coli in CD, where they have been identified within macrophages11 and inside granulomata,12 there is no evidence that they invade the mucosa in UC and their ability to elicit an IL-8 response from intestinal epithelial cells,4 and thus to promote the superficial neutrophil recruitment13 that typifies UC, is a likely alternative mechanism for a pathogenic effect. Moreover, the demonstration that unequivocous pathogens such as Salmonella spp, Shigella spp, Yersinia spp, and Vibrio chol-
*erae* can only invade the gut mucosa via the specialized M cells that overlay Peyer’s patches in the small intestine and lymphoid follicles in the colon and cannot invade the mucosa via normal colon epithelial cells\(^\text{14}\) makes it unlikely that the AIEC found in IBD and colon cancer invade normal colon epithelial cells, although it is plausible that these bacteria might invade M cells and thus provoke the initial lesions of CD which probably occur at Peyer’s patches or lymphoid follicles.\(^\text{15}\)

In this study we set out to characterize the mechanisms involved in the epithelial IL-8 response to IBD and colon cancer mucosal *E. coli* isolates with particular emphasis on assessing the relative importance of the AIEC phenotype in mediating this response, the downstream signaling mechanisms involved, and the effects of drugs used to treat IBD.

### MATERIALS AND METHODS

#### Bacterial Strains and Growth Conditions

*Escherichia coli* were previously isolated from colonic mucosal biopsies of patients with CD, colon cancer, UC, and a control population (irritable bowel syndrome [IBS]/sporadic polyposis).\(^\text{4}\) Thirty-three isolates were studied including 7 from CD, 6 from UC, 14 from colon cancer, and 6 control patient (irritable bowel or sporadic polyp) *E. coli*. The CD *E. coli* were isolated from 7 CD patients (2 were receiving corticosteroids and azathioprine, respectively, and the remainder were on 5-aminosalicylic acid [5-ASA]); UC *E. coli* were isolated from 5 patients (all 5 on 5-ASA and 2 were receiving corticosteroids); control *E. coli* were isolated from 2 patients (IBS and sporadic polyps), and colon cancer *E. coli* were isolated from 11 patients (2 patients undergoing resection received intravenous cephalosporin and metronidazole). The phylogenetic group of each *E. coli* (A, B1, B2, or D) was defined using in this study are summarized in Table 1. The characteristics of the bacterial strains used in this study are summarized in Table 1.

Isolates were cultured on Columbia agar with overnight incubation in air at 37°C. Prior to infection of cultured epithelial cells, bacteria were washed in sterile PBS and adjusted to an OD\(_{550}\)nm of 0.125 (equivalent to 150 \(\times\) 10\(^6\) CFU/mL). In some studies *E. coli* were heat-inactivated at 60°C for 30 minutes. To demonstrate whether *E. coli* possessed flagella, isolates were stab-inoculated into 0.3% motility agar. To assess for the presence of curli fimbriae, *E. coli* isolates were grown on nutrient agar supplemented with 30 µg/mL Congo red for 48 hours at 26°C.

#### Reagents

SP600125 (an inhibitor of c-Jun N-terminal kinase [JNK]), SB203580 (a pyridinyl imidazole inhibitor of p38-MAPK pathway), and Bay11-7082 (an irreversible inhibitor of NF-κB activation, through inhibition of IκB-α phosphorylation) were all obtained from Calbiochem (Nottington, UK). U0126 (a MEK inhibitor that inhibits the kinase activity of ERK1/2) was obtained from Promega (Madison, WI). Monoclonal antibodies to JNK1 (SC1648), phospho-JNK1/2 (SC6254), and polyclonal antibodies to ERK2 (SC154G) and TLR5 (SC10742) were all from Santa Cruz Biotechnology (San Francisco, CA). Other monoclonals included anti-phosphoERK1/2 (Cell Signaling Technology, Beverly, MA), pan-antibody (Neomarkers, Fremont, CA) and anti-Ras (Calbiochem). Polyclonal rabbit anti-flagellar serum was a kind gift from Dr. J. Giron (Microbiology & Immunology, University of Arizona, Tucson). An NF-κB p65 subunit siRNA kit (Cell Signaling Technology) included anti p65 and ERK2 antibodies.

Recombinant proteins included human IL-8 (Peprotech EC, London, UK), TNF-α (R&D Systems, Abingdon, UK), and *E. coli* flagellin (Inotek, Beverly, MA). *E. coli* O127:B8 lipopolysaccharide (LPS), polymixin B, hydrocortisone, methyl α-D-mannopyranoside, and protease type XIV were all from Sigma (Poole, UK). Human leukocyte elastase was from Elastin Products (Owensville, MO). 5-ASA (mesalamine) was a kind gift from Dr. S. Andersson (Pharmacia, Uppsala, Sweden). The carcinoembryonic antigen-related cell adhesion molecule (CEACAM)-binding polypeptide R7 was produced using the pQE30 expression system as described previously.\(^\text{17}\) The R7 polypeptide had been shown to inhibit the binding of respiratory and urogenital pathogens (*M. catarrhalis, H. influenzae, N. gonorrhoeae, and N. meningitidis*) via inhibition of CEACAM-dependent bacterial adhesion.\(^\text{17}\)

#### Cell Culture

Human colon cancer cell lines HT29 and T84 were obtained from the European Collection of Animal Cell Culture (Public Health Laboratory Service, Wiltshire, UK). HT29 cells were cultured in DMEM containing 10% FCS, 100 U/mL penicillin, 100 µg/mL streptomycin, and 4 mM glutamine. HEK293 uroepithelial cells, stably transfected with pUNO-hTLR5 (encoding human toll-like receptor 5), pUNO-LacZ (encoding β-galactosidase) or vector alone were obtained from Invitrogen (San Diego, CA). HEK293 were cultured in complete DMEM supplemented with 10 µg/mL basicidin. Polarized T84 model epithelia were cultured in Ham’s F12 medium (10% FCS, penicillin and streptomycin) on 0.45 µm collagen-coated permeable supports (Millipore, Watford, UK). Monolayers with a transepithelial electrical resistance (TEER) of >800 \(\Omega\)/cm\(^2\) were used for assessment of flagellin transcytosis. All cell lines were maintained at 37°C in 5% CO\(_2\), 95% air.
Assessment of IL-8 Release from HT29 Cells in Response to Mucosal *E. coli* Isolates and Bacteria-free *E. coli* Culture Supernatants

HT29 cells (8 × 10⁴ per well) were infected, in triplicate, for up to 8 hours, with apical addition of whole *E. coli* isolates from each disease group (7 CD, 14 colon cancer, 6 UC, and 6 controls) at a multiplicity of infection (MOI) of 10 (≈7 × 10⁶ CFU/mL) in keeping with previous studies of bacterial adherence to intestinal cell lines.² ³ IL-8 released to the medium was measured by enzyme-linked immunosorbent assay (ELISA). TNF-α (2 ng/mL, 4 hours) was used as a control stimulus.

Pooled bacteria-free *E. coli* culture supernatants were generated from *E. coli* isolates, 6 each pooled separately from

---

### TABLE 1. Characteristics of *E. coli* Strains Used

| *E. coli* Isolate | Disease Group          | Hemagglutination Status | Afa/Dr Cluster | Curli Fimbriae | Adherence to I407 Cells | Invasion of I407 Cells | Adherence to HT29 Cells | Invasion of HT29 Cells | Phylotype | Replication Within Macrophages/Adherent Monocytes |
|------------------|------------------------|-------------------------|----------------|----------------|--------------------------|------------------------|-------------------------|------------------------|-----------|-----------------------------------------------|
| HM95²            | Crohn’s disease        | -                       | +              | +              | +                        | +                      | +                       | +                      | A         | +                                             |
| HM154³           | Crohn’s disease        | -                       | +              | -              | +                        | -                      | +                       | -                      | B1        | +                                             |
| HM427³           | Crohn’s disease        | +                       | +              | +              | +                        | +                      | +                       | +                      | B2        | +                                             |
| HM580³           | Crohn’s disease        | +                       | +              | -              | +                        | +                      | +                       | +                      | D         | +                                             |
| HM605³           | Crohn’s disease        | -                       | -              | +              | +                        | -                      | -                       | -                      | B2        | +                                             |
| HM615³           | Crohn’s disease        | -                       | -              | +              | -                        | -                      | -                       | -                      | B2        | +                                             |
| HM670            | Crohn’s disease        | -                       | -              | -              | +                        | +                      | +                       | -                      | B2        | +                                             |
| LF82             | Crohn’s disease        | -                       | n/a            | n/a            | +                        | n/a                    | n/a                     | n/a                    | B2        | +                                             |
| HM44²            | Colon cancer           | +                       | -              | +              | +                        | +                      | +                       | -                      | B2        | n/a                                           |
| HM164³           | Colon cancer           | -                       | -              | +              | +                        | +                      | +                       | +                      | B2        | n/a                                           |
| HM196            | Colon cancer           | -                       | -              | -              | +                        | -                      | -                       | +                      | D         | n/a                                           |
| HM213            | Colon cancer           | +                       | -              | +              | +                        | +                      | +                       | -                      | B2        | n/a                                           |
| HM229            | Colon cancer           | +                       | +              | +              | +                        | +                      | +                       | -                      | B2        | n/a                                           |
| HM288³           | Colon cancer           | +                       | -              | +              | +                        | +                      | +                       | -                      | B2        | n/a                                           |
| HM329            | Colon cancer           | +                       | -              | -              | +                        | -                      | -                       | -                      | B2        | n/a                                           |
| HM334            | Colon cancer           | -                       | -              | +              | +                        | -                      | +                       | +                      | B2        | n/a                                           |
| HM356³           | Colon cancer           | -                       | -              | -              | +                        | +                      | -                       | -                      | B1        | n/a                                           |
| HM358            | Colon cancer           | +                       | +              | +              | +                        | +                      | +                       | +                      | A         | n/a                                           |
| HM497            | Colon cancer           | -                       | -              | -              | +                        | +                      | -                       | +                      | A         | n/a                                           |
| HM544³           | Colon cancer           | +                       | -              | +              | +                        | +                      | -                       | -                      | B2        | n/a                                           |
| HM545            | Colon cancer           | +                       | -              | +              | +                        | +                      | -                       | -                      | B2        | n/a                                           |
| HM550³           | Colon cancer           | -                       | -              | +              | +                        | +                      | +                       | -                      | D         | n/a                                           |
| HM250³           | Ulcerative colitis     | +                       | -              | +              | n/a                      | n/a                    | n/a                     | n/a                    | B2        | n/a                                           |
| HM295³           | Ulcerative colitis     | -                       | -              | -              | n/a                      | n/a                    | n/a                     | n/a                    | B2        | n/a                                           |
| HM378³           | Ulcerative colitis     | -                       | -              | n/a            | n/a                      | n/a                    | n/a                     | n/a                    | B2        | n/a                                           |
| HM380³           | Ulcerative colitis     | -                       | -              | n/a            | n/a                      | n/a                    | n/a                     | n/a                    | B2        | n/a                                           |
| HM387³           | Ulcerative colitis     | -                       | -              | n/a            | n/a                      | n/a                    | n/a                     | n/a                    | B2        | n/a                                           |
| HM394³           | Ulcerative colitis     | -                       | -              | +              | n/a                      | n/a                    | n/a                     | n/a                    | B2        | n/a                                           |
| HM452³           | Control                | -                       | -              | n/a            | n/a                      | n/a                    | n/a                     | n/a                    | B2        | n/a                                           |
| HM454³           | Control                | +                       | -              | +              | n/a                      | n/a                    | n/a                     | n/a                    | B2        | n/a                                           |
| HM455³           | Control                | -                       | -              | -              | n/a                      | n/a                    | n/a                     | n/a                    | B2        | n/a                                           |
| HM456³           | Control                | +                       | -              | +              | n/a                      | n/a                    | n/a                     | n/a                    | B2        | n/a                                           |
| HM488³           | Control                | -                       | -              | -              | n/a                      | n/a                    | n/a                     | n/a                    | B2        | n/a                                           |
| HM489³           | Control                | -                       | -              | +              | n/a                      | n/a                    | n/a                     | n/a                    | B2        | n/a                                           |

²Denotes strains used for generation of pooled bacteria-free *E. coli* culture supernatant.

n/a indicates data not available.
4 disease groups (UC, CD, colon cancer, and control patients). Bacterial suspensions (OD_{550nm} 0.125) were 0.2 μm-filtered and supernatants confirmed bacteria-free by overnight culture on Columbia agar. Epithelial cells were treated with 50 μL supernatant/mL culture medium and IL-8 release compared to supernatants predigested (3 h, 37°C) with either 0.25 μM leukocyte elastase or 20 μg/mL Streptococcal protease XIV to remove flagellin, as described previously. Heat-inactivated elastase and protease (90°C, 15 min) were used as controls.

### Quantification of IL-8 Release

Following treatment, culture medium and cell monolayers were harvested and processed as previously described. IL-8 was measured in triplicate using a solid-phase sandwich ELISA with anti-human IL-8 capture and detection antibodies (790A 28G2 and 893C 4G2; Biosource, Camarillo, CA). Within and between assay coefficients of variation were 10.1% (n = 3) and 13% (n = 7), respectively.

### Investigation of the Role of Flagella, Outer Membrane Vesicles (OMV), and LPS in Mediating the Release of IL-8

Flagella from CD (HM427) and colon cancer (HM288) E. coli isolates were purified by ammonium sulfate precipitation. Purity was monitored by SDS-PAGE, immunoblotting, and transmission electron microscopy (TEM). OMVs were isolated by ultracentrifugation from a 0.2 μm-filtered E. coli culture supernatant, pooled from 6 mucosal E. coli (5 hemagglutination-positive and 1 negative isolate, from 3 UC patients) or E. coli HM427 supernatant, as described previously. In separate experiments, pretreatment of bacterial suspensions with polymixin B (PMB; 10 μg/mL, 1 h) was used to block any action of LPS. IL-8 release evoked by LPS derived from E. coli serotype O127:BB (1 μg/mL) was used as a control for the inhibitory action of polymixin B.

### Assessment of Flagellin Transcytosis

Polarized T84 model epithelia were apically colonized with 10^8 CFU/mL CD E. coli HM427. After 4 hours, flagellin present within the apical and basolateral media was analyzed by SDS-PAGE as per Lyons et al followed by immunoblotting with anti-flagellar serum.

### Analysis of Flagellin-TLR5 and Fimbrial-receptor Interactions Involved in Mucosal E. coli-mediated IL-8 Release

To assess the role of TLR5, HT29, and HEK293 cells (expressing TLR5, LacZ, or vector alone) were apically infected (MOI 10), for 4 hours with each of 33 E. coli and also with pooled bacteria-free E. coli culture supernatants, purified flagella (1 μg/mL), recombinant flagellin (1 μg/mL), or OMVs (from pooled UC isolates). TNF-α (2 ng/mL) was used as a positive control.

To investigate the role of CEACAMS and Type 1 (mannose-dependent) fimbriae, HT29 cell monolayers were pretreated with anti-CEACAM peptide rD-7 (1 μg/mL) or methyl α-D-mannopyranoside (10 mM) for 60–90 minutes. Subsequently, cells were incubated for 4 hours with apical addition of whole E. coli isolates. Inhibitors were maintained in the medium throughout the period of infection. IL-8 released into the medium was measured by ELISA and compared to untreated controls.

### Amplification of fliC and Sequence Alignment of Flagellin (FliC) Protein Monomers from Mucosa-associated E. coli

Amplification of fliC was performed by PCR in a total reaction volume of 50 μL containing 1 μL of bacterial supernatant, 100 nM each of fliC oligonucleotide primers (sense 5’ ATGGCACAAGTCATTAAT 3’ and anti-sense 5’ TTAACCTGCAGTATAGA 3’) and 1.1x PCR Master Mix (ABgene, Surrey, UK). DNA sequencing was performed by Lark Technologies (Essex, UK) and deduced amino-acid residues from fliC ampli-con sequences were analyzed using CLUSTAL W (1.83) multiple sequence alignment software. E. coli flagellin (FliC) sequences were compared with respect to those regions previously determined to be important for TLR5 recognition.

### Analysis of Intracellular Signal Pathways Involved in Mucosal E. coli-mediated IL-8 Release

Following apical infection with each of the 33 E. coli isolates, IL-8 release was assessed in HT29 cells pretreated (all 10 μM) with U0126 (to block ERK1/2 activity), SB203580 (to inhibit p38 MAPK pathway), or SP600125 (to inhibit JNK activity) for 60–90 minutes. Inhibitors were present throughout the 4-hour infection. In separate experiments, MAPK activation by CD and colon cancer isolates, for up to 60 minutes, was confirmed by SDS-PAGE and immunoblotting as described previously. Phorbol 12-myristate 13-acetate (PMA) (0.25 μM, 20 min) was used as a positive control for MAPK activation.

Activation of Ras, the upstream guanine-nucleotide binding protein that stimulates the Raf-MEK-MAPK pathway, was assessed over a 30-minute infection. Glutathione S transferase (GST)-K85A RBD (Ras-binding domain of Raf1) fusion protein was used to pull down active (GTP-
bound) Ras, as described elsewhere. Total lysates and pull-down samples were analyzed by SDS-PAGE and immunoblot using antibody against Ras. Equal loading was confirmed using ERK2 antibody.

To assess the role of NF-κB, IL-8 release was assessed in response to each of the 33 E. coli isolates from HT29 cells pretreated with IκBα phosphorylation inhibitor Bay11-7082 (10 μM, 60 min) to block NF-κB activation. Inhibitor was present throughout the 4-hour infection. Downregulation of NF-κB was also performed using p65 subunit siRNA duplexes introduced to 50% confluent HT29 cells in the presence of 8 μL/mL TransIT-TKO (Cambridge Bioscience) 24 hours before treatment with flagella or apical addition of whole E. coli. Suppression of the p65 subunit was confirmed by immunoblotting.

Effect of 5-ASA (Mesalamine) and Hydrocortisone on Mucosal E. coli-mediated IL-8 Release

HT29 cells were pretreated for 1 hour with 5-ASA (2.5–20 mM) or hydrocortisone (10–100 μM), followed by addition of 0.2 μm-filtered pooled UC E. coli culture supernatant. After 4 hours IL-8 release was measured by ELISA.

Quantification of Cellular Protein and DNA

Protein and double-stranded DNA concentrations of cell lysates were determined using the bicinchoninic acid assay (Sigma) and PicoGreen (Molecular Probes, Paisley, UK) as per the manufacturer’s instructions.

Cytotoxicity Assay

5-ASA and hydrocortisone were assessed for cytotoxicity toward the cultured epithelial cells using the adenylate kinase assay (ToxiLight Non-Destructive Cytotoxicity Bioassay Kit, Cambrex Bio, Cambridge, MA) as per the manufacturer’s instructions.

Statistical Analysis

Independent sample groups were assessed for both normality and for equality of variances. As appropriate, treatment groups were analyzed using Student’s t-test or Mann–Whitney U-test. For multiple treatment groups, 1-way or Kruskall–Wallis analysis of variance (ANOVA) was employed, followed by pairwise comparisons of treatment means (StatsDirect v2.3.1; Sale, UK). Differences were considered significant when P < 0.05.

RESULTS

Mucosal E. coli Isolates Stimulate IL-8 Release from Colonic Epithelial Cells

All mucosal E. coli isolates from CD (n = 7) and colon cancer (n = 14) were shown to stimulate the release of IL-8 from HT29 cells in a time-dependent manner (Fig. 1A). A lower IL-8 release was seen in response to E. coli isolates from control patients (IBS/sporadic polyposis) (236 ± 100 pg IL-8/mL at 4 hours [all mean ± SD unless indicated otherwise], n = 6) and those from UC (236 ± 58 pg/mL, n = 6) compared with isolates from CD (689 ± 298 pg/mL, n = 7) and colon cancer (532 ± 415 pg/mL, n = 14; P < 0.0001, ANOVA) (Fig. 1B).

Intracellular IL-8 content was also increased in response to treatment with CD and colon cancer E. coli, rising from a median of 2.4 pg/mL (range 1.2–51 pg/mL) at 0.5 hours to a median of 261 pg/mL (range 108–601 pg/mL) at 8 hours as compared to uninfected control cells: 2 pg/mL (1.3–2.2) and 60 (59.5–69.5) pg/mL at 0.5 and 8 hours, respectively (P < 0.01 ANOVA; n = 21, i.e., 7 CD and 14 colon cancer isolates). No significant changes were seen in cellular double-stranded DNA levels in the HT29 cells when infected with mucosal E. coli isolates over the 8-hour incubation period (201 ± 73 ng/mL DNA) at the end of the treatment period compared to 207 ± 85 ng/mL in untreated controls (n = 21).

Magnitude of IL-8 Release Correlates with Ability of E. coli to Cause Hemagglutination

Our previous work had shown a strong correlation between the ability of mucosal E. coli to hemagglutinate human red blood cells and their ability to adhere to intestinal epithelial cells in culture. Our previous work had shown a strong correlation between the ability of mucosal E. coli to hemagglutinate human red blood cells and their ability to adhere to intestinal epithelial cells in culture. E. coli that cause hemagglutination (n = 16) induced a greater IL-8 response from HT29 cells (548 ± 428 pg IL-8/mL) than nonhemagglutinators (281 ± 253 pg/mL, n = 17; P < 0.0001 Mann–Whitney U) (Fig. 1C); heat-inactivation of CD E. coli isolate HM427 only caused a modest reduction in its ability to induce an IL-8 response: 203 ± 53 pg/mL at 4 hours compared with 323 ± 84 pg/mL for live E. coli HM427 (n = 3, P = 0.01, Mann–Whitney U).

Pooled Bacteria-free E. coli Culture Supernatant Induces a Substantial IL-8 Response

Twenty-four E. coli isolates, 6 each from control patients (including 1 hemagglutinator), CD (including 4 hemagglutinators), UC (including 1 hemagglutinator), and colon cancer (including 3 hemagglutinators) were pooled to form a bacterial suspension and a bacteria-free supernatant was derived by passage through a 0.2-μm filter. Filtered supernatants caused an IL-8 response: 203 ± 53 pg/mL at 4 hours with 323 ± 84 pg/mL for live E. coli HM427 (n = 3, P = 0.01, Mann–Whitney U).

IL-8 Response to Bacteria-free E. coli Culture Supernatants Is Reduced by Protease and Leukocyte Elastase Digestion

Pretreatment of bacteria-free E. coli supernatants with either protease XIV (20 μg/mL for 3 h at 37°C) or leukocyte

166
elastase (0.25 μM for 3 h at 37°C) caused a substantial reduction in the IL-8 response from HT29 cells compared with untreated *E. coli* supernatant. IL-8 response to pooled bacteria-free *E. coli* culture supernatant was reduced by 46 ± 19% with protease XIV (*P = 0.003, ANOVA*) and 68 ± 30% with elastase (*P < 0.0001, ANOVA*) (Fig. 2). These findings would be compatible with flagellin as the stimulus for IL-8 release.

**Purified Flagella Stimulate Comparable IL-8 Release to Whole Bacteria**

Flagella, isolated from 7 × 10⁶ *E. coli*, either colon cancer isolate HM288 or the CD isolate HM427 (Fig. 3A), caused an IL-8 release of 178 ± 40 pg/mL and 148 ± 38 pg/mL.

**FIGURE 1.** Stimulation of IL-8 release from HT29 colon epithelial cells by mucosal *E. coli*. A: CD mucosal *E. coli* (*n = 7*) stimulate IL-8 release from confluent HT29 cells in a time-dependent manner. IL-8 release was measured by ELISA and data expressed as pg/mL (mean ± SEM). Solid bar represents IL-8 release at 8 hours induced by 2 ng/mL TNF-α (*n = 6*). Significant differences from 8 hours basal release, ***P < 0.001* (ANOVA). B: A significantly greater IL-8 response was seen following treatment using mucosal *E. coli* isolated from patients with CD (*n = 7*) and colon cancer (*n = 14*) compared to *E. coli* isolated from UC (*n = 6*) or control patients (*n = 6*). Significant differences from basal IL-8 response, ***P < 0.001, **P < 0.001* and significant differences from control and UC patient responses, (***P < 0.001 (Kruskal-Wallis ANOVA)). C: Hemagglutinating *E. coli* isolates (*n = 16*) elicited a greater IL-8 response from HT29 cells than nonagglutinating *E. coli* strains (*n = 17*), ***P < 0.0001* (Mann–Whitney U).
pg/mL, respectively, as compared to 220 ± 34 pg/mL and 201 ± 29 pg/mL in response to equivalent amounts of whole bacteria (Fig. 3B). Almost all (99 ± 5%, n = 3) of the IL-8-stimulatory activity of the bacterial supernatant was shown to be attributable to an OMV preparation (Fig. 4A). OMV are known to contain proteins relevant to pathogenicity29 but immunoblotting showed flagellin to be present within the purified OMV preparations (Fig. 4B) and TEM confirmed the presence of flagella associated with OMVs (Fig. 4C), again compatible with flagellin as the major stimulant for IL-8 response to the bacterial supernatants.

LPS from Mucosal E. coli Contributes Little to the IL-8 Response

Inhibition of LPS by preincubation of bacterial suspension with 10 μg/mL polymyxin B for 1 hour only caused a reduction of 7 ± 4% in IL-8 response to 2 mucosal E. coli isolates from CD.

TLR-5 Dependence of IL-8 Response to 19/33 E. coli Isolates

Having shown that flagellin was a major determinant of the IL-8 response to the mucosal E. coli, we investigated the role of the known flagellin-receptor, TLR5, by testing the IL-8 response in HEK293 cells with and without transfected TLR5. Nineteen of the 33 E. coli isolates tested (8/14 colon cancer isolates and 5/7 CD and 2/6 each of UC and 4/6 control E. coli) elicited IL-8 release in a TLR5-dependent fashion, defined as a response to TLR5-expressing HEK293 cells ≥20% of that seen with HT29 cells (Fig. 5A). For these E. coli the median IL-8 response was 394 ± 253 pg/mL in HEK-hTLR5 cells compared to 32 ± 42 pg/mL in HEK293-LacZ cells. For E. coli where the IL-8 release was not mediated by flagellin-TLR5 interaction, the median IL-8 response was only 23 ± 18 and 38 ± 37 pg/mL, respectively, from HEK293-hTLR5 and HEK293-LacZ cells (n = 14). TNF-α (2 ng/mL, for 4 h) evoked a similar IL-8 response from TLR5- and β-galactosidase-expressing HEK293 cells. All 33 E. coli isolates were able to induce an IL-8 release from HT29 cells, with a median IL-8 release of 405 ± 346 pg/mL. HT29 cells were also shown to express TLR5 (Fig. 5B).

Amplification of fliC from representative mucosa-associated E. coli isolates, able (n = 4) or unable (n = 5) to induce TLR5-dependent IL-8 production in HEK293-hTLR5 cells, showed some variation in amplicon length but no correlation with IL-8 response in HEK293-hTLR5 cells (data not shown). In addition, deduced amino-acid sequences (aligned using the CLUSTAL W algorithm) demonstrated no significant differences in flagellin residues within those regions previously determined to be important for TLR5 recognition,23-25 indicating that all our mucosa-associated E. coli isolates are likely to make flagellin molecules that can be recognized by TLR5 (see Table 2). All 33 isolates were shown to possess flagella and to be motile on 0.3% agar plates.

Among the 14 E. coli isolates that did not mediate IL-8 release via TLR5, the IL-8 response from HT29 cells was considerably greater for hemagglutinators (median 513 pg/mL, range 277–813) than for nonhemagglutinating strains (median 175 pg/mL, range 48–295; P = 0.004 Mann–Whitney U). Study of pooled bacterial supernatants from each disease group and isolated OMV confirmed the TLR5-mediated IL-8 response (see Fig. 5C).

Curli fimbriae, an extracellular matrix component of Enterobacteriaceae (including commensal E. coli), have recently been shown to be involved in IL-8 release from HT29 cells via interaction with flagellin.30,31 We therefore assessed all 33 E. coli isolates in this study for the presence of curli fimbriae and its association with TLR5-dependent epithelial cell IL-8 release. Overall, 17/33 E. coli isolates possessed curli fimbriae. There was a good association between presence of curli and the magnitude of IL-8 response from HEK293-hTLR5 cells (P = 0.05, unpaired t-test). However, there was no relationship seen between curli and hemagglutination status of the E. coli, nor any association with isolates from specific patient groups.

It is noteworthy that supernatants from CD, colon cancer, and UC E. coli isolates, unlike the whole bacteria, all cause similar IL-8 responses, suggesting that the enhanced IL-8 responses to whole bacteria from CD and colon cancer are not explained by flagellin-TLR5 interaction.

Following a 4-hour incubation of polarized T84 epithelium with CD mucosa-associated E. coli HM427, an AIEC,4 applied to the apical aspect, flagellin was undetectable in the basolateral medium as determined by immunoblot analysis (n
suggesting that transcytosis of flagellin had not occurred even though a significant IL-8 response was seen (249.1 ± 26.4 pg IL-8/mL) compared with control untreated cells (43.6 ± 19.8 pg IL-8/mL, P < 0.0001).

IL-8 Response to *E. coli* Is Neither Dependent on Interaction with Host CEACAMs Nor Involves Bacterial Mannose-dependent Fimbrial Adhesins

CEACAM6 was recently shown to act as a receptor for AIEC adhesion and was found to be upregulated in the ileal mucosa of CD patients. Pretreatment of HT29 cells with 1 µg/mL recombinant polypeptide rD-7, an antimicrobial agent that blocks the interactions of a number of mucosal pathogens with CEACAM-expressing epithelial cells, failed to reduce the overall IL-8 response to all 33 *E. coli* isolates (IL-8 release in presence of rD-7: 298 ± 66 pg IL-8/mL, compared to untreated controls 323 ± 72 pg/mL). Only 3/33 *E. coli* isolates showed a reduction in IL-8 response of >20% (range 21%–32%) with rD-7 but there was neither any disease group association, relation to hemagglutination status, nor correlation with possession of Afa/Dr. We also assessed the possible inhibitory effect of addition of 10 mM α-methyl mannospyranoside; however, this showed a similar IL-8 response (301 ± 68 pg/mL, n = all 33 *E. coli* isolates) compared with untreated controls. These studies suggest little or no role for Afa/CEACAM interaction in the IL-8 response.

IL-8 Response to *E. coli* Isolates Is Mediated via ERK1/2 and p38 MAPK Activation but Not NF-κB Activation

We next investigated the intracellular signaling pathways responsible for the IL-8 response. Inhibition of ERK1/2 activation by pretreatment with 10 µM U0126 for 1 hour reduced IL-8 release in response to whole bacteria by 77 ± 14%, from 610 ± 355 to 194 ± 107 pg IL-8/mL across all 33 *E. coli* isolates (P < 0.0001, ANOVA) (Fig. 6A). Similarly, inhibition of p38 MAPK activation by SB203580 (10 µM) reduced IL-8 release by 84 ± 18%, from 509 ± 322 to 149 ± 81 pg IL-8/mL (P < 0.0001, ANOVA; n = 33) (Fig. 6A). By contrast, inhibition of c-Jun N-terminal kinase (JNK) activation by pretreatment of HT29 cells with 10 µM SP600125 for 90 minutes caused a more modest reduction in

**FIGURE 4.** IL-8 release induced by pooled bacteria-free *E. coli* culture supernatant is mediated via a shed outer membrane vesicle (OMV) preparation. A: All of the IL-8 response evoked by a bacteria-free *E. coli* culture supernatant can be accounted for by a sedimented OMV fraction prepared by ultracentrifugation from the same 6 pooled UC *E. coli* isolates (both ***P < 0.0001 [ANOVA], compared with basal IL-8 release). The supernatant, free of pelleted OMV (as confirmed by TEM), did not significantly stimulate IL-8 release above basal levels. B: Immunoblot of OMV and flagella, both isolated from a CD *E. coli* isolate HM427, demonstrating flagellin immunoreactivity in the OMV fraction. C: TEM revealed that *E. coli* OMVs are ~100–150 nm in size, electron-dense, and surrounded by an outer membrane. Flagella (arrow) were also associated with OMVs. Scale bar = 50 nm.
IL-8 response. IL-8 release was reduced by only 36 ± 28%, from 402 ± 277 to 285 ± 228 pg IL-8/mL across all 33 E. coli isolates (P < 0.0001, ANOVA) (Fig. 6A). Treatment of HT29 cells with mucosal CD E. coli HM427 resulted in the activation of Ras between 1 and 5 minutes, returning to basal levels 30 minutes after infection. Peak activation occurred at 2 minutes, with a 1.8 ± 0.62 (mean ± SEM; n = 3) fold increase in active (GTP-bound) Ras (Fig. 6B,C). This was followed by subsequent activation of ERK1/2 within 5 minutes of infection (Fig. 6D,E). Peak activation was seen at 15 minutes, with 1.15 ± 0.05 and 1.94 ± 0.25-fold increase in phosphorylation of ERK1 (p44) and ERK2 (p42), respectively (mean ± SEM; n = 3). Phosphorylation of ERK1/2 was sustained for at least 60 minutes (Fig. 6D,E).

Blockade of NF-κB activation using the IκBα phosphorylation inhibitor Bay 11-7082 (10 μM for 1 h) reduced E. coli-induced IL-8 release by 29 ± 23%, from 349 ± 108 to 255 ± 129 pg/mL across all 33 E. coli isolates (P < 0.0001, ANOVA). A greater than 50% reduction in IL-8 release by NF-κB inhibition was only observed in response to 11/33 E. coli isolates. For 2 of these isolates, colon cancer E. coli HM288 and CD E. coli HM427, both hemagglutinators, coinubcation with Bay 11-7082 caused >80% inhibition of IL-8 response. Pretreatment of HT29 cells for 24 hours with siRNA to down-regulate the p65 subunit of NF-κB resulted in a 48 ± 8% and 45 ± 19% reduction in IL-8 release in response to HM288 and HM427, respectively (P < 0.001, ANOVA; n = 3) (Fig. 7A,B). These studies show that the IL-8 response is largely ERK/MAPK-dependent, with relatively little input from JNK or NF-κB activation.
IL-8 Response to Pooled Bacteria-free E. coli Culture Supernatant Is Inhibited by Mesalamine (5-ASA) but Not by Hydrocortisone at Therapeutically Relevant Concentrations

Mesalamine, a drug effective in the treatment of UC, is known to inhibit MAPK. We assessed the effect of mesalamine on the E. coli IL-8 response and also the effect of hydrocortisone, a drug that is also effective in UC but that probably has its main action via inhibition of NF-κB activation. Pretreatment of HT29 cells with 5-ASA dose-dependently inhibited the IL-8 response to a bacteria-free E. coli culture supernatant pooled from 6 UC isolates (Fig. 8A). Maximal inhibition of IL-8 release (97% of control) was seen with 20 mM 5-ASA and a plausible therapeutic concentration, 5 mM 5-ASA, inhibited IL-8 release by 45% (P < 0.05 ANOVA) (Fig. 8B). At the maximal concentrations tested, 5-ASA (20 mM) and hydrocortisone (100 μM), the adenylate kinase levels released into the culture medium was within 90%–110% of vehicle-treated control cells.

**DISCUSSION**

In this study, we demonstrate that mucosal E. coli isolates from IBD and colon cancer induce an IL-8 response from HT29 colon epithelial cells that is mediated by activation of the ERK1/2 and p38 MAPK pathways but not by activation of NF-κB. This activity is inhibited by therapeutic concentrations of mesalamine but not hydrocortisone. For many of the E. coli isolates, similar IL-8 responses are present in the UC and control E. coli isolates. This study has shown a substantial IL-8 response from the UC and control E. coli isolates. It needs to be recognized that these are not completely healthy controls and that there is increasing evidence that bacteria may have a role in the development of sporadic adenomas and colon cancer.7

Flagellin initiates the inflammatory response to several pathogenic organisms including enteropathogenic E. coli. Flagellin sequences were aligned using CLUSTAL W (1.83) multiple sequence alignment software. Shaded amino acids indicate sequence differences. Asterisks indicate equivalent amino acid residues previously determined by others to be important for TLR5 recognition.23-25

*a E. coli evoked IL-8 release was determined in HEK293-hTLR5 cells.

**TABLE 2. Sequence Alignment of Flagellin (FliC) Protein Monomers from Mucosal E. coli**

| E. coli able to induce TLR5-dependent IL-8 production* |
|--------------------------------------------------------|
| HM550 flic 57 QTTEGAELNNLQRILETVQASTGTNSDSLDSIQDEIKSR 100 474 TTNPLALDAISSIDKFRSSLGAIQNRLLDSAV 507 |
| HM387 flic 60 QTTEGAELNNLQRILETVQASTGTNSDSLDSIQDEIKSR 103 477 TTNPLALDAISSIDKFRSSLGAIQNRLLDSAV 510 |
| HM164 flic 54 QTTEGAELNNLQRILETVQASTGTNSDSLDSIQDEIKSR 97 481 TKDPLALDAISSIDKFRSSLGAIQNRLLDSAV 514 |
| HM095 flic 54 QTTEGAELNNLQRILETVQASTGTNSDSLDSIQDEIKSR 97 318 TTNPLALDAISSIDKFRSSLGAIQNRLLDSAV 351 |

| E. coli unable to induce TLR5-dependent IL-8 production* |
|--------------------------------------------------------|
| HM544 flic 54 QTTEGAELNNLQRILETVQASTGTNSDSLDSIQDEIKSR 97 434 TSDPLALDAISSIDKFRSSLGAIQNRLLDSAV 467 |
| HM489 flic 61 QTTEGAELNNLQRILETVQASTGTNSDSLDSIQDEIKSR 104 478 TTNPLALDAISSIDKFRSSLGAIQNRLLDSAV 511 |
| HM394 flic 60 QTTEGAELNNLQRILETVQASTGTNSDSLDSIQDEIKSR 103 487 TKDPLALDAISSIDKFRSSLGAIQNRLLDSAV 520 |
| HM358 flic 56 QTTEGAELNNLQRILETVQASTGTNSDSLDSIQDEIKSR 99 473 TTNPLALDAISSIDKFRSSLGAIQNRLLDSAV 506 |
| HM295 flic 54 QTTEGAELNNLQRILETVQASTGTNSDSLDSIQDEIKSR 97 481 TKDPLALDAISSIDKFRSSLGAIQNRLLDSAV 514 |

Flagellin sequences were aligned using CLUSTAL W (1.83) multiple sequence alignment software. Shaded amino acids indicate sequence differences. Asterisks indicate equivalent amino acid residues previously determined by others to be important for TLR5 recognition.23-25

*a* E. coli evoked IL-8 release was determined in HEK293-hTLR5 cells.

Flagellin initiates the inflammatory response to several pathogenic organisms including enteropathogenic E. coli. Flagellin sequences were aligned using CLUSTAL W (1.83) multiple sequence alignment software. Shaded amino acids indicate sequence differences. Asterisks indicate equivalent amino acid residues previously determined by others to be important for TLR5 recognition.23-25
(EPEC), enteroaggregative E. coli (EAggEC), and Salmonella spp and aflagellate mutants of these organisms are unable to induce an IL-8 response. The present study illustrates that intestinal bacteria need not possess classical pathogenicity genes in order to elicit this response and also shows that epithelial IL-8 release may be promoted by such bacteria without any need for cellular invasion. This finding is consistent with previous reports of nonpathogenic E. coli strains capable of inducing cytokine response from explanted colonic mucosa and from intestinal epithelial cells in vitro.

The flagellin receptor, TLR5, is largely expressed on the basolateral aspect of intestinal epithelial cells, so this raises the question of how this receptor will be accessed by the mucosal E. coli without cellular invasion. Although there is some evidence from human colonic epithelium and murine ileal epithelium of low-level expression of TLR5 on the apical surface, the healthy colonic epithelium is probably not responsive to luminal flagellar stimulation. This situation changes in the presence of inflammation, however. Mice cotreated with dextran sulfate sodium (DSS) and flagellin...
develop a much more florid colitis than those treated with DSS alone, implying that flagellin plays an important role in the development and progression of colitis once the mucosal barrier is impaired. Thus, the impaired barrier that probably exists as a result of altered tight junction structure and function in UC and CD is likely to be sufficient for flagellin to access basolateral TLR5 in vivo. The weakened mucus barrier in ulcerative colitis would be an additional factor.

In mammals, 3 major MAPK pathways have been identified: MAPK-ERK1/2, stress-activated p38 MAPK (α, β, γ, and δ), and JNK1/2/3. In most cases activation of MAPK signaling networks occurs by small G proteins such as Ras, Rac, and Rap1, but also involves other enzymes. Our finding that the epithelial IL-8 response to mucosal E. coli isolates is mediated via Ras-ERK1/2 and p38 MAPK is consistent with the reported involvement of MAPK in the host cell responses to infection with pathogenic E. coli such as enterohemorrhagic E. coli (EHEC), EPEC, and EAggEC. Phosphorylation of MAPK leads to downstream activation of transcription factors including NF-κB and AP-1, both of which upregulate IL-8 transcription. It has been shown that p38 MAPK, JNK1/2, and ERK1/2 are activated in the inflamed colonic mucosa of IBD patients, with the p38α isoform exhibiting the greatest increase in phosphorylation.

There is preliminary evidence that MAPK inhibitors may be therapeutically effective in IBD.

5-ASA (mesalamine)-based compounds are used widely in the therapy of IBD and have a variety of effects that include inhibition of MAPK. They act locally at the mucosal level and efficacy is related to mucosal concentrations of the drug. In vitro effects of 5-ASA include inhibition of prostaglandin and leukotriene biosynthesis, proinflammatory cytokine production, and inhibition of both ERK and NF-κB pathways. The antiinflammatory effect of 5-ASA has also been shown to be dependent on its interaction with the peroxisome proliferator-activated receptor gamma (PPARγ), a member of the nuclear receptor superfamily. Some of these effects are complementary; inhibition of ERK phosphorylation, for example, will result in reduced phosphorylation and hence reduced degradation of PPARγ. Here, we demonstrate that clinically and biologically relevant concentrations of 5-ASA inhibit the IL-8 release triggered by mucosal E. coli isolates. In contrast to 5-ASA, hydrocortisone was only able to abolish epithelial IL-8 release at 20-fold higher concentrations than are relevant clinically. This is consistent with reports that hydrocortisone only reduces cytokine levels at supratherapeutic concentrations in the respiratory epithelium.
lum in response to coronoviral infection.\textsuperscript{57} Thus, the epithelial cell is the main target cell for 5-ASA therapy, whereas hydrocortisone exerts its effect mainly by acting on other cells such as T cells,\textsuperscript{58} monocytes,\textsuperscript{59} macrophages,\textsuperscript{60} and dendritic cells.\textsuperscript{61} It is also consistent with the fact that inhibition of NF-κB activation, which is a principal target for corticosteroids, only had a minor effect on epithelial IL-8 response to mucosal \textit{E. coli} in the current study.

The potential role of adhesive and invasive \textit{E. coli} in colon cancer is intriguing. There are similarities between the biology of sporadic colon cancer and IBD-associated cancer.\textsuperscript{57} Epithelial activation of NF-κB is critical in the development of inflammation-associated cancer, probably acting via suppression of apoptosis.\textsuperscript{62} The adherent and adhesive mucosal \textit{E. coli} isolates are able to invade colon cancer cell lines in vitro\textsuperscript{4} and the present study also suggests that at least some of these bacteria are able to activate NF-κB in these colon cancer cells. It is therefore reasonable to speculate that adherence to or invasion of dysplastic epithelial cells by such \textit{E. coli} could have an important role in determining progression from dysplasia to cancer.

Inhibition of the mechanisms that are essential for the epithelial IL-8 response to mucosa-associated \textit{E. coli} represents a logical approach to therapy in IBD, perhaps particularly in UC, where the inflammation is more superficial and where there is little evidence of bacterial invasion.

\begin{acknowledgments}

The authors thank the staff of the University of Liverpool Physiological laboratory, including Drs. I. Prior and C. Muncke (Biomedical Electron Microscopy Unit) and Dr. D. Hammond (who kindly provided GST-K85A RBD fusion protein). We also thank Dr. Lu-Gang Yu (School of Clinical Science) for invaluable advice on immunoblotting of phosphorylated proteins of the MAPK signal cascade.

\end{acknowledgments}

\begin{references}

1. Hoffmann JC, Pawlowski NN, Kuhl AA, et al. Animal models of inflammatory bowel disease: an overview. \textit{Pathobiology}. 2002;70:121–130.

2. Darfeuille-Michaud A, Neut C, Barnich N, et al. Presence of adherent \textit{Escherichia coli} strains in ileal mucosa of patients with Crohn’s disease. \textit{Gastroenterology}. 1998;115:1405–1413.

3. Swidzinski A, Ladhoff A, Pernthaler A, et al. Mucosal flora in inflammatory bowel disease. \textit{Gastroenterology}. 2002;122:44–54.

4. Martin HM, Campbell BJ, Hart CA, et al. Enhanced \textit{Escherichia coli} adherence and invasion in Crohn’s disease and colon cancer. \textit{Gastroenterology}. 2004;127:80–93.

5. Alpern JA, Sasaki M, Bitarama SV, et al. Invasive \textit{E. coli} strains are increased in Crohn’s disease. \textit{Gastroenterology}. 2006;130:A-362.

6. Kotловskи R, Bernstein CN, Sepheri S, et al. High prevalence of \textit{Escherichia coli} belonging to the B2+D phylogenetic group in inflammatory bowel disease. \textit{Gut}. 2007;56:669–675.

7. Martinez-Medina M, Aldeguer X, Gonzalez-Huix F, et al. Abnormal microbiota composition in the ileocolonic mucosa of Crohn’s disease patients as revealed by polymerase chain reaction-denaturing gradient gel electrophoresis. \textit{Inflamm Bowel Dis}. 2006;12:1136–1145.

8. Mylonaki M, Rayment NB, Rampton DS, et al. Molecular characterization of rectal mucosa-associated bacterial flora in inflammatory bowel disease. \textit{Inflamm Bowel Dis}. 2005;11:481–487.

9. Sokol H, Lepage P, Seksik P, et al. Temperature gradient gel electrophoresis of fecal 16S rRNA reveals active \textit{Escherichia coli} in the microbiota of patients with ulcerative colitis. \textit{J Clin Microbiol}. 2006;44:3172–3177.

10. Simpson KW, Dogan B, Rishiv M, et al. Adherent and invasive \textit{Escherichia coli} is associated with granulomatous colitis in boxer dogs. \textit{Infect Immun}. 2006;74:4778–4792.

11. Liu Y, van Kruiningen HJ, West AB, et al. Immunocytochemical evidence of \textit{Listeria}, \textit{Escherichia coli}, and \textit{Streptococcus} antigens in Crohn’s disease. \textit{Gastroenterology}. 1995;108:1396–1404.

12. Ryan P, Kelly RG, Lee G, et al. Bacterial DNA within granulomas of patients with Crohn’s disease-detection by laser capture microdissection and PCR. \textit{Am J Gastroenterol}. 2004;99:1539–1543.

13. Matushima K, Morishita K, Yoshimura T, et al. Molecular cloning of a human monocyte-derived neutrophil chemoattractant factor (MDNCF) and the induction of MDNCF mRNA by interleukin 1 and tumor necrosis factor. \textit{J Exp Med}. 1988;167:1883–1893.

14. Sansonetti PJ, Phalipon A. M cells as ports of entry for enteroinvasive pathogens: mechanisms of interaction, consequences for the disease process. \textit{Semin Immunol}. 1999;11:193–203.

15. Fujimura Y, Kamoi R, Iida M. Pathogenesis of aphthoid ulcers in Crohn’s disease: correlative findings by magnifying colonoscopy, electron microscopy, and immunohistochemistry. \textit{Gut}. 1996;38:724–712.

16. Clermont O, Bonacorsi S, Bingen E. Rapid and simple determination of the \textit{Escherichia coli} phylogenetic group. \textit{Appl Environ Microbiol}. 2000;66:4555–4558.

17. Hill DJ, Edwards AM, Rowe HA, et al. Carcinomycobacterial antigen-related cell adhesion molecule (CEACAM)-binding recombinant polypeptide confers protection against infection by respiratory and urogenital pathogens. \textit{Mol Microbiol}. 2005;55:1515–1527.

18. Lopez-Boado YS, Espinola M, Bahr S, et al. Neutrophil serine proteins act as cleavage bacterial flagellin, abrogating its host response-inducing activity. \textit{J Immunol}. 2004;172:509–515.

19. Leiper K, Campbell BJ, Jenkinson MD, et al. Interaction between bacterial peptides, neutrophils and goblet cells: a possible mechanism for neutrophil recruitment and goblet cell depletion in colitis. \textit{Clin Sci}. 2001;101:395–402.

20. de Oliveira-Garcia D, D’Agnol M, Rosales M, et al. Characterization of flagella produced by clinical strains of \textit{Stenotrophomonas maltophilia}. \textit{Emerg Infect Dis}. 2002;8:918–923.

21. Wai SN, Takade A, Amako K. The release of outer membrane vesicles from the strains of enteroaggregative \textit{Escherichia coli}. \textit{Microb Infect}. 1995;39:451–456.

22. Lyons S, Wang L, Casanova J, et al. \textit{Salmonella typhimurium} transcytes flagellin via an SPI2-mediated vesicular transport pathway. \textit{J Cell Sci}. 2004;117:5771–5780.

23. Andersen-Nissen E, Smith KD, Strobe KL, et al. Evasion of Toll-like receptor 5 by flagellated bacteria. \textit{Proc Natl Acad Sci U S A}. 2005;102:9247–9252.

24. Donnelly MA, Steiner TS. Two nonadjacent regions in enteroga segregative \textit{Escherichia coli} flagellin are required for activation of toll-like receptor 5. \textit{J Biol Chem}. 2002;277:40456–40461.

25. Smith KD, Andersen-Nissen E, Hayashi F, et al. Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility. \textit{Nat Immunol}. 2003;4:1247–1253.

26. Singh R, Subramanian S, Rhodes JM, et al. Peanut lectin stimulates proliferation of colon cancer cells by interaction with glycosylated CD44v6 isoforms and consequential activation of c-Met and MAPK: functional implications for disease-associated glycosylation changes. \textit{Glycobiology}. 2006;16:459–469.

27. Gutkind JS. Regulation of mitogen-activated protein kinase signaling networks by G protein-coupled receptors. \textit{Sci STKE}. 2000:RE1.

28. Chapman K, Hall DJ. Quantifying the activation of the small molecular weight G-protein Ras. \textit{BAMBED}. 2005;33:22–27.

29. Davis JM, Carvalho HM, Rasmussen SB, et al. Cytotoxic necrotizing factor type 1 delivered by outer membrane vesicles of uropathogenic \textit{Escherichia coli} attenuates polymorphonuclear leukocyte antimicrobial activity and chemotaxis. \textit{Infect Immun}. 2006;74:4401–4408.

30. Rochon M, Römling U. Flagellin in combination with curli fimbiae

\end{references}
elicits an immune response in the gastrointestinal epithelial cell line HT-29. *Microbes Infect.* 2006;8:2027–2033.

31. Wehkamp J, Fellermann K, Herrlinger KR, et al. Mechanisms of disease: defensins in gastrointestinal diseases. *Nat Clin Pract Gastroenterol Hepatol.* 2005;2:406–415.

32. Barnich N, Carvalho FA, Glasser AL, et al. CEACAM6 acts as a receptor for adherent-invasive *E. coli*, supporting ileal mucosa colonization in Crohn disease. *J Clin Invest.* 2007;117:1566–1574.

33. Kaiser GC, Yan F, Polk DB. Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonicocytes. *Gastroenterology.* 1999;116:602–609.

34. Rousseaux C, Lefebvre B, Dubuquoy L, et al. Intestinal anti-inflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. *J Exp Med.* 2005;201:1205–1215.

35. Elliott PR, Powell-Tuck J, Gillespie PE, et al. Prednisolone absorption in acute colitis. *Gut.* 1980;21:49–51.

36. Kassinen A, Krogius-Kurikka L, Ma¨kivuokko H, et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. *Gastroenterology.* 2007;133:24–33.

37. Rhodes JM, Campbell BJ. Inflammation and colorectal cancer: IBD-associated and sporadic cancer compared. *Trends Mol Med.* 2002;8:10–16.

38. Khan MA, Kang J, Steiner TS. Enteropathogenic *Escherichia coli* flagellin-induced interleukin-8 secretion requires Toll-like receptor 5-dependent p38 MAP kinase activation. *Immunology.* 2004;112:651–660.

39. Zeng H, Carlson AQ, Guo Y, et al. Flagellin is the major proinflammatory determinant of enteropathogenic *Salmonella.* J Immunol. 2003;171:3668–3674.

40. Zhou X, Giron JA, Torres AG, et al. Flagellin of enteropathogenic *Escherichia coli* stimulates interleukin-8 production in *T84* cells. *Infect Immun.* 2003;71:2120–2129.

41. Boruell N, Casellas F, Antolin H, et al. Effects of nonpathogenic bacteria on cytokine secretion by human intestinal mucosa. *Am J Gastroenterol.* 2003;98:865–870.

42. Bambou JC, Giraud A, Menard S, et al. In vitro and ex vivo activation of the TLR5 signaling pathway in intestinal epithelial cells by a commensal *Escherichia coli* strain. *J Biol Chem.* 2004;279:42984–42992.

43. Gewirtz AT, Navas TA, Lyons S, et al. Cutting edge: bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression. *J Immunol.* 2001;167:1882–1885.

44. Cario E, Podolsky DK. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. *Infect Immun.* 2000;68:7010–7017.

45. Rhee SH, Im E, Riegler M, et al. Pathophysiological role of Toll-like receptor 5 engagement by bacterial flagellin in colonic inflammation. *Proc Natl Acad Sci U S A.* 2005;102:13610–13615.

46. Gitter AH, Wullstein F, Fromm M, et al. Epithelial barrier defects in ulcerative colitis: characterization and quantification by electrophysiological imaging. *Gastroenterology.* 2001;121:1320–1328.

47. Soderholm ID, Olaison G, Peterson KH, et al. Augmented increase in tight junction permeability by luminal stimuli in the non-inflamed ileum of Crohn’s disease. *Gut.* 2002;50:307–313.

48. Swidsinski A, Loening-Baucke V, Theissig F, et al. Comparative study of the intestinal mucus barrier in normal and inflamed colon. *Gut.* 2007;56:343–350.

49. Hommes DW, Peppelenbosch MP, van Deventer SJ. Mitogen-activated protein (MAP) kinase signal transduction pathways and novel anti-inflammatory targets. *Gut.* 2003;52:144–151.

50. Berin MC, Darfeuille-Michaud A, Egan LJ, et al. Role of EHEC O157:H7 virulence factors in the activation of intestinal epithelial cell NF-kappaB and MAP kinase pathways and the upregulated expression of interleukin 8. *Cell Microbiology.* 2002;4:635–648.

51. Czerucka D, Dahan S, Mograbi B, et al. Implication of mitogen-activated protein kinases in *T84* cell responses to enteropathogenic *Escherichia coli* infection. *Infect Immun.* 2001;69:1298–1305.

52. Waetzig GH, Seegert D, Rosenstiel P, et al. p38 mitogen-activated protein kinase is activated and linked to TNF-alpha signaling in inflammatory bowel disease. *J Immunol.* 2002;166:5342–5351.

53. Hommes D, van den Blink B, Plasse T, et al. Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn’s disease. *Gastroenterology.* 2002;122:7–14.

54. Frieri G, Giacomelli R, Pimpo M, et al. Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis. *Gut.* 2000;47:410–414.

55. Sharon P, Ligumsky M, Rachmilewitz D, et al. Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine. *Gastroenterology.* 1978;75:638–640.

56. Hedvat M, Jain A, Carson DA, et al. Inhibition of HER-kinase activation prevents ERK-mediated degradation of PPARgamma. *Cancer Cell.* 2004;5:565–574.

57. Cinatl Jr, Michaeili M, Morgenstern B, et al. High-dose hydrocortisone reduces expression of the pro-inflammatory chemokines CXCL8 and CXCL10 in SARS coronavirus-infected intestinal cells. *Int J Mol Med.* 2005;15:323–327.

58. Paliogianni F, Ahuja SS, Balow JP, et al. Novel mechanism for inhibition of human T cells by glucocorticoids. Glucocorticoids inhibit signal transduction through IL-2 receptor. *J Immunol.* 1993;151:4081–4089.

59. Breuninger LM, Dempsey WL, Uhl J, et al. Hydrocortisone regulation of interleukin-6 protein production by a purified population of human peripheral blood monocytes. *Clin Immunol Immunopathol.* 1993;69:205–214.

60. Linden M, Brattsand R. Effects of a corticosteroid, budesonide, on alveolar macrophage and blood monocyte secretion of cytokines: differential sensitivity of GM-CSF, IL-1 beta, and IL-6. *Pulm Pharmacol.* 1994;7:43–47.

61. de Jong EC, Vieira PL, Kalinski P, et al. Corticosteroids inhibit the production of inflammatory mediators in immature monocyte-derived DC and induce the development of tolerogenic DC3. *J Leukoc Biol.* 1999;66:201–204.

62. Greten FR, Eckmann L, Greten TF, et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. *Cell.* 2004;118:285–296.